Ultra-Precision Optics Coating Equipment for 300 mm substrates

In light of the continuously increasing challenges, as it pertains to film uniformity and characteristics, SOLAYER GmbH offers a production tool to address this.

The new AVIOR M-300 is specifically designed to guarantee high throughput and reliable production of precision optics with outperforming film uniformity and characteristics.

Its’ unique combination of a Sputter-Up configuration with Dual Rotary Magnetrons offers unrivaled competitive benefits such as process stability, lowest particle count, minimal service time and cost of ownership.

Although the AVIOR M-300 can accommodate as much as 12 units of 300 mm substrates per run, its‘ flexibility in production is unrivaled, with carrier systems for various substrates sizes adaptations (such as 48 x 150 mm substrates).

Uninterrupted vacuum in the process chamber is assured with the AVIOR M-300 due to the load lock design. Remarkably, the dual-rotary sputter magnetrons with different materials (reservoirs ≈ 1,500cm3) serve several weeks of continuous production. The modular design which can incorporate as much as four materials and two plasma sources allows growth rates of about 10 nm/sec. This design capability offers a superior variety of dielectric, metallic and hybrid layers of multiple materials without the need for material change.

The AVIOR M-300 is equipped with an in-situ deposition growth control and has no need for calibration and test-runs even for stack designs of several hundred layers. Film thickness uniformity is guaranteed as well as prevention of deposited in-film defects. This results in stable and predictable deposition processes over weeks. Extremely dense, amorphous and shift free layers can be deposited.

With layer growth akin to ‘imaging’, the layers have almost no intrinsic roughness and a unique uniformity of down to 0.2 %.

SOLAYER’s AVIOR M-300 puts the Precision in Precision Optics.

Originalmeldung direkt auf PresseBox lesen
Mehr von Firma PresseBox

WKR Walter Austria: Start-up of another Herbold film wash line

To extend its facility in Wels, Austria, WKR Walter has chosen a complete integrated solution from HERBOLD Meckesheim GmbH, based in Meckesheim/Germany. The key component of the plant is the latest generation of HERBOLD’s VWE pre-wash system, hydrocyclone separation and a twin centrifugal drying step. WKR Walter recycles post consumer film.

The infeed of the line is baled material, sourced from Germany, based on DSD 310 spec. It provides for the efficient cleaning of the material a hydrocyclone separation step as a key requirement for the production of high-grade recyclate for manufacturing of thin-walled film . HERBOLD and WKRWalter are looking back to a long-term cooperation. All the three existing wash lines have been upgraded by HERBOLD Meckesheim GmbH with hydrocyclones in the last couple of years, having allowed WKRWalter to upgrade the quality of the washed flakes to a new level. For the first time WKRWalter is able to operate a film wash line without the need of a thermal drying unit, thanks to the efficient operation of the HERBOLD centrifuge.

The new line is designed for 10.000 t/year, WKR Walter is already discussing a further expansion.

Originalmeldung direkt auf PresseBox lesen
Mehr von Firma PresseBox

Digital Twins: The What, Why and How

You’ve probably heard a lot about digital twins lately. And with good reason. They’re an essential part of any company’s digital transformation. But what are digital twins and why do people want them?

What is the Definition of a Digital Twin?

Simply put, a digital twin is a virtual representation of a product or process. This means that you can create your production line virtually before building it in the real world to see how it will work and what issues may arise.

Once the production line is up and running in the real world sensors on the line can feed data to its digital twin. The digital twin can then be used to analyze how well the line is running and make predictions, based on how it’s run in the past, on how it’ll run in the future.

The results of the analysis can be turned into actions in the real world. For example, oven temperatures could be adjusted on the production line or replacement parts could be requested and maintenance scheduled.

With enough data you can even run scenarios to see how your production line will be affected under different circumstances.

The Benefits of a Digital Twin

Defining a digital twin is easy. Listing all of the benefits takes a bit longer. Below are just a few of the major benefits of using a digital twin of your products, plants and processes:

  • Faster New Product Introduction (NPI): By utilizing a digital twin, you can replicate the planned production process of your new product and game out all the scenarios of what could go wrong before you even start to build your production line. This prevents costly adjustments later on when physical, rather than digital equipment, needs to be adjusted.
  • Reduced Downtime: Digital twins of your equipment can predict how long that equipment is expected to run for, based on past data, before it requires maintenance. If the twin is being fed with current data from the real equipment then it can modify its estimate based on its performance deterioration. This predictive maintenance feature allows you to plan maintenance during existing stoppages and avoid breakdowns which will reduce overall downtime.
  • Reduced Scrap and Rework Costs: A digital twin of your product can be run through your manufacturing processes to predict where issues may arise. By utilizing data from previous product production runs you can see where similar issues are likely to arise with your next product. The digital twin of a production line doesn’t need to live in isolation. By training it with data from other production line processes it becomes better equipped to predict and reduce scrap and rework.
  • Predict Gains/Losses of Modifying Production: With enough data on your equipment, processes and products you can calculate whether making adjustments to your manufacturing process are financially viable. If you run that piece of equipment 10% faster will the benefits outweigh the costs of more frequent maintenance? Don’t forget, the digital twin doesn’t just utilize physical data – one of its biggest benefits is in its ability to integrate financial data, such as the cost of materials and labor.
  • Reduced Training Costs: Using augmented reality (AR), live video of equipment on the plant floor is overlaid with information fed from the digital twin. This could include the current status of various components or it could guide an engineer through repair procedures. The use of augmented reality can greatly reduce training requirements, increase overall safety and raise the efficiency of people working on the production line.
  • Improved Supply Chain Management: Moving beyond your plant, a digital twin of the supply chain feeding into your manufacturing processes can be tweaked and fine-tuned so that procurement, logistics and delivery can be predicted and optimized. Sharing data with your suppliers will allow you to extend and strengthen the digital thread of your products so you can make the right tactical and strategic decisions with the best information available, reducing costs and supporting your Supply Chain Management (SCM).

Using Digital Twin technology is part of the Digital Transformation journey that you can make, today. It allows fact-based decision making, more agile operations, and faster employee engagement, all contributing to a more responsive, productive plant.

Originalmeldung direkt auf PresseBox lesen
Mehr von Firma PresseBox

RavenQuest completes first cannabis shipment to Wayland Group

RavenQuest BioMed Inc. (CSE: RQB OTCQB: RVVQF Frankfurt: 1IT) (the “Company” or “RavenQuest” – https://www.commodity-tv.net/c/search_adv/?v=298814 ) a federally licensed producer of cannabis, is pleased to announce it has completed its first shipment of bulk cannabis to Wayland Group.

The shipment was made as part of a larger agreement between RavenQuest and Wayland group, whereby RavenQuest will supply up to 8,000 kg of bulk cannabis to Wayland Group. The agreement spans the entirety of calendar 2019.

CEO, George Robinson commented that “it has been a pleasure dealing with Ben Ward and the entire team at Wayland Group. We are very excited to complete this first shipment, which represents the beginning of our agreement as we fulfill our commitment to supply premium cannabis to our partners at Wayland.”

“The new license at our Edmonton facility brings significantly more capacity onstream, dramatically increasing our revenue potential for 2019. In addition to this agreement, we have also signed an MOU to supply cannabis to the British Columbia Liquor Distribution Branch. Between these two distribution channels and based upon prevailing B2B market prices, we’re confident we can ramp up revenue to north of the budgeted $44.5 million for 2019.” Robinson continued.

For more information, view RavenQuest’s updated website at www.rqbglobal.com.

Follow RavenQuest on Twitter @RQBGlobal

About RavenQuest BioMed Inc.

RavenQuest BioMed Inc. is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized research & development. RavenQuest is a licensed producer with facilities located in Markham, Ontario and Edmonton, Alberta.

RavenQuest maintains a research partnership with McGill University focused upon cultivar (strain) recognition, plant stabilization and yield maximization of the cannabis plant. The Company focuses on partnerships with Indigenous communities.

On Behalf of the Board of Directors of AVENQUEST BIOMED INC.

"George Robinson" Chief Executive Officer

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

Cautionary Note Regarding Forward-Looking Statements

All statements in this press release, other than statements of historical fact, are "forward-looking information" with respect to the Company within the meaning of applicable securities laws, including statements with respect to anticipated production capacity. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited to those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Readers are cautioned that budgeted revenue is based upon prevailing prices for the supply of cannabis products in business-to-business transactions, and assumes annual production of 11,000 kilograms of cannabis from the Company’s Edmonton facility. A number of factors may cause actual results to differ materially from budgeted amounts, including changes in the market price and demand for cannabis products, interruptions in production and operations at the Company’s facility and an evolving government and regulatory landscape.

Originalmeldung direkt auf PresseBox lesen
Mehr von Firma PresseBox

RavenQuest Provides Update on Recent License and Production Capacity Expansion

RavenQuest BioMed Inc. (CSE: RQB OTCQB: RVVQF Frankfurt: 1IT) (the “Company” or “RavenQuest” – https://www.commodity-tv.net/c/search_adv/?v=298814 ) a federally licensed producer of cannabis, is pleased to provide an update following receipt of its cultivation license at its Edmonton facility and the capacity expansion that comes with it.

Licensing of the Edmonton facility represents an inflection point for the Company, increasing its licensed annual cannabis production capacity to 11,000 kg—a 275% increase.

RavenQuest currently has a supply agreement with Wayland Group, whereby RavenQuest has agreed to supply them with up to 8,000 kg of cannabis in 2019.  RavenQuest has also entered a memorandum of understanding with the British Columbia Liquor Distribution Branch (“BCLDB”) and expects to enter into an agreement in to sell the remainder of its cannabis production to them in 2019.

With respect to ramping up production at the newly licensed Edmonton facility, RavenQuest CEO, George Robinson stated “we have an experienced team in place at both Edmonton and Markham facilities to ensure starting material is expedited safely from the Markham facility to the Edmonton facility.  Our experience in cannabis consulting, together with the seasoned plant expertise of Dr. Simerjeet Kaur and her team will enable us to bring production online in Edmonton properly and at a rapid pace”.

“With the Edmonton facility online, RavenQuest is on track to fulfill its supply agreement with the Wayland Group and expects to be in a position to supply the BCLDB with cannabis once a definitive supply agreement is reached” Robinson continued.

In addition to an increase in cannabis revenue for 2019, RavenQuest also anticipates a record year for its Services Division, with several new clients signing contracts including, notably, a one year agreement with Bonify valued at $1.5 million.

Once legalized, RavenQuest intends to deliver on its broader growth strategy to provide value-added products across a wide spectrum of delivery options including vaporization, edibles and beverages.  “Our plans include a diversified product offering of unique experiences for cannabis consumers.  These products will differ substantially from the fractional distillates planned by our competitors.  Instead, we will place the emphasis on the full plant extract, with the myriad flavours and profiles that come with passing through the full plant experience to value added products” stated Robinson.

“As we move past the licensing phase,” stated Robinson, “2019 promises to be an unprecedented year for RavenQuest and our stakeholders.  We are excited to take the Company from the buildout phase to the revenue and profitability phase, and continuing to accelerate our growth trajectory.  There is much to look forward to for RavenQuest BioMed in 2019.”

For more information, view RavenQuest’s updated website at www.rqbglobal.com.

The BCLDB is responsible for regulating private retail cannabis licensing and the distribution of cannabis to retail stores in British Columbia’s legal adult-use recreational cannabis marketplace. The MOU does not represent a binding purchase agreement, and any distribution of cannabis products to the BCLDB is subject to the negotiation of such an agreement on the terms specified by the BCLDB. The Company will provide additional information regarding the BCLDB supply and distribution process as it becomes available.

Follow RavenQuest on Twitter @RQBGlobal

About RavenQuest BioMed Inc.

RavenQuest BioMed Inc. is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized research & development.  RavenQuest is a licensed producer with facilities located in Markham, Ontario and Edmonton, Alberta.

RavenQuest maintains a research partnership with McGill University focused upon cultivar (strain) recognition, plant stabilization and yield maximization of the cannabis plant.  The Company focuses on partnerships with Indigenous communities.

On Behalf of the Board of Directors of
RAVENQUEST BIOMED INC.

"George Robinson"
Chief Executive Officer

For further information, please contact: Mathieu McDonald, Corporate Communications
1-877-282-1586

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

Cautionary Note Regarding Forward-Looking Statements

All statements in this press release, other than statements of historical fact, are "forward-looking information" with respect to the Company within the meaning of applicable securities laws, including statements with respect to anticipated production capacity.  The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes.  By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved.  These risks and uncertainties include but are not limited to those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements.  The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Originalmeldung direkt auf PresseBox lesen
Mehr von Firma PresseBox

Ravenquest Secures Health Canada Cultivation License at Edmonton Facility

RavenQuest BioMed Inc. (CSE: RQB OTCQB: RVVQF Frankfurt: 1IT) (the “Company” or “RavenQuest” – https://www.commodity-tv.net/c/search_adv/?v=298814) a federally-licensed producer of cannabis, is pleased to announce it has secured a Health Canada License to Cultivate at the Company’s flagship Edmonton facility.  The license allows RavenQuest to begin cannabis production inside the revolutionary Orbital Garden 2.0 grow technology at its ultra-modern Edmonton production facility.  The Edmonton facility increases RavenQuest’s production capacity by 275%, adding 7,000 kg of annual capacity and bringing the Company’s total production capacity to approximately 11,000 kg per year.

George Robinson, CEO of RavenQuest, stated “this is a very exciting time and inflection point for our organization.  This milestone catapults our company toward dramatic cannabis production and revenue increases for 2019.   We have been busy preparing for this pivotal moment.  Our Edmonton team is ready and all equipment is in place, including our Orbital Garden 2.0 technology.  Starting material has been carefully prepared and curated at our Markham facility and will be moved to Edmonton to begin production immediately” Robinson continued.

“Production will be ramped up rapidly and efficiently in order to meet supply agreements with our provincial partner, BCLDB, as well as major bulk buyer, Wayland Group” stated Robinson.  “We have already pre-sold all cannabis production from our Markham and Edmonton facilities for the calendar year of 2019” he continued.

For more information, access RavenQuest’s investor presentation, fact sheet and videos here.

About RavenQuest BioMed Inc.

RavenQuest BioMed Inc. is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized research & development.  RavenQuest is a licensed producer with facilities located in Markham, Ontario and Edmonton, Alberta.

RavenQuest maintains a research partnership with McGill University focused upon cultivar (strain) recognition, plant stabilization and yield maximization of the cannabis plant.  The Company focuses on partnerships with Indigenous communities.

On Behalf of the Board of Directors of
RAVENQUEST BIOMED INC.

"George Robinson"
Chief Executive Officer

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

Cautionary Note Regarding Forward-Looking Statements

All statements in this press release, other than statements of historical fact, are "forward-looking information" with respect to the Company within the meaning of applicable securities laws, including statements with respect to anticipated production capacity.  The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes.  By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved.  These risks and uncertainties include but are not limited to those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements.  The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Originalmeldung direkt auf PresseBox lesen
Mehr von Firma PresseBox

Jenoptik opens new production facility in France

New production space, offices and a modern metrology laboratory were built on an industrial site southeast of Bayeux, only a few kilometers from the previous Jenoptik location. The new building has a total area of around 2,500 square meters. Construction began in spring 2018, the employees moved into their new workplaces at the beginning of this year.

At the opening ceremony on April 3, 2019, Jenoptik President & CEO Stefan Traeger and CFO Hans-Dieter Schumacher welcomed customers, suppliers and partners as well as political representatives. The opening was at the same time the starting point of a regional event on the latest trends in industrial measurement technology to be held regularly.

With this investment Jenoptik has state-of-the-art production and sales environment for its high-precision industrial measurement machines, which are used in industry and automotive manufacturing. In France, Jenoptik’s customers include renowned automotive manufacturers and supplier companies. As regards the global metrology business of Jenoptik, France is the excellence center of pneumatic metrology.

The original corporate building from the 1930s had been extended again and again over decades and no longer met the requirements of modern production environments. ”In the new building, we can offer our customers, employees and partners a modern environment and are also an attractive partner for universities and technical colleges,” says site manager Marc Schuh. Contact with research institutions is to be considerably expanded.

In the metrology market segment Jenoptik acquired the French company ETAMIC S.A. in 2006 and merged it with its industrial metrology business. Jenoptik’s other major metrology sites are located in the geographic centers of the global automotive industry: Besides Germany and France, these are Rochester Hills near Detroit in the USA, Shanghai in China and Pyeongtaek in Korea.

The industrial metrology business belongs to the Light & Production division, which Jenoptik is currently strongly expanding. In addition to acquisitions to strengthen the global business Jenoptik is also investing in existing locations. The new production complex in Rochester Hills, Michigan, went into operation in 2017. In Villingen-Schwenningen, the German metrology headquarters, a new production complex is currently being built for around 11 million euros.

Originalmeldung direkt auf PresseBox lesen
Mehr von Firma PresseBox

Jenoptik eröffnet neues Produktionsgebäude in Frankreich

Nur wenige Kilometer vom bisherigen Jenoptik-Standort entfernt sind auf einem Industriegelände südöstlich von Bayeux neue Produktionsflächen, Büroräume und ein modernes Messtechnik-Labor entstanden. Der Neubau hat eine Fläche von insgesamt etwa 2.500 Quadratmetern. Baubeginn war im Frühjahr 2018, die Mitarbeiter haben ihre neuen Arbeitsplätze Anfang dieses Jahres bezogen.

Zur feierlichen Eröffnung am 3. April 2019 begrüßten der Vorstand der JENOPTIK AG, Stefan Traeger und Hans-Dieter Schumacher, Vertreter der Politik sowie Kunden, Lieferanten und Partner des Messtechnik-Spezialisten. Die Eröffnungsfeier war zugleich Auftakt einer von nun an regelmäßigen regionalen Veranstaltung rund um neueste Trends in der industriellen Messtechnik.

Mit der Investition schafft Jenoptik ein modernes Produktions- und Vertriebsumfeld für ihre hochpräzise industrielle Messtechnik, die in der Industrie sowie Automobilfertigung eingesetzt wird. In Frankreich zählen namhafte Automobil- und Zulieferunternehmen zu den Kunden der Jenoptik. Für das globale Messtechnikgeschäft der Jenoptik ist Frankreich das Exzellenzzentrum für pneumatische Messtechnik.

Das alte Firmengebäude aus den 1930er Jahren war über Jahrzehnte hinweg immer wieder erweitert worden und entsprach nicht mehr den Anforderungen an moderne Produktionsumgebungen. „Im neuen Gebäude können wir unseren Kunden, Mitarbeitern und Partnern ein modernes Umfeld bieten, und sind auch für Universitäten und Fachhochschulen ein attraktiver Partner“, so Standortleiter Marc Schuh. Der Kontakt zu Forschungseinrichtungen soll erheblich ausgebaut werden.

Im Marktsegment Messtechnik hatte Jenoptik 2006 die französische ETAMIC S.A. übernommen und mit der industriellen Messtechnik der Jenoptik zusammengeführt. Weitere große Standorte der industriellen Messtechnik sind die Zentren der weltweiten Automobilindustrie: Neben Deutschland und Frankreich sind dies in den USA Rochester Hills nahe Detroit, Shanghai in China und Pyeongtaek in Korea.

Die industrielle Messtechnik gehört zur Division Light & Production, die Jenoptik aktuell stark ausbaut. Neben Akquisitionen zur Stärkung des globalen Geschäfts investiert Jenoptik auch in die Standorte. 2017 wurde der neue Produktionskomplex in Rochester Hills in Betrieb genommen. In Villingen-Schwenningen, Hauptsitz der industriellen Messtechnik in Deutschland, entsteht aktuell ein neuer Produktionskomplex für rund 11 Mio Euro.

Originalmeldung direkt auf PresseBox lesen
Mehr von Firma PresseBox

OEKO-TEX® Prüfkriterien 2019 – Neuregelungen sind am 1. April endgültig in Kraft getreten

Elementare Themen für die OEKO-TEX® Gemeinschaft sind seit jeher Verbraucherschutz und Nachhaltigkeit entlang der textilen Wertschöpfungskette. Aus diesem Grund werden zu Beginn eines jeden Jahres die bestehenden Richtlinien des OEKO-TEX® Produktportfolios aktualisiert und damit neueste wissenschaftliche Erkenntnisse sowie Branchentrends adaptiert. Nach einer Übergangsfrist sind am 1. April 2019 die OEKO-TEX® Neuregelungen für alle Zertifizierungssysteme und Dienstleistungen endgültig in Kraft getreten. Eine Übersicht über die Neuregelungen aller Produkte finden Sie hier. Die aktuellsten Änderungen betreffen den ECO PASSPORT by OEKO-TEX® Standard.

ECO PASSPORT by OEKO-TEX®
Die Basis für eine nachhaltige Produktion von Textilien und Lederwaren ist der Einsatz von umweltfreundlichen Chemikalien. Die ECO PASSPORT by OEKO-TEX® Zertifizierung zielt ausdrücklich auf die Vermeidung von unerwünschten Chemikalien ab, und zwar noch bevor sie in die globale Lieferkette gelangen. Dafür werden eine Vielzahl von Chemikalien, darunter Farbmittel, Mittel zum Abkochen, Klebstoffe, Tinten, Pigmente und Hilfsstoffe in einem vertraulichen, dreistufigen Prozess analysiert, der bestätigt, dass die Formulierungen und einzelnen Inhaltsstoffe bestimmte Kriterien im Hinblick auf Nachhaltigkeit, Sicherheit und die Einhaltung gesetzlicher Bestimmungen erfüllen.

Die Änderungen im Überblick:

Aufnahme von Lederchemikalien
Nach der Einführung des LEATHER STANDARD by OEKO-TEX® für schadstoffgeprüfte Lederprodukte sowie der Sustainable Textile & Leather Production Zertifizierung (STeP) für umweltfreundliche und nachhaltige Lederproduktion können in Kürze neben Textilchemikalien auch Lederchemikalien entsprechend den Vorgaben des ECO PASSPORT by OEKO-TEX® getestet und zertifiziert werden.

Neue Substanzen in den Grenzwertkatalogen
Diverse Substanzen wurden neu in die Grenzwertkataloge aufgenommen. Dazu gehören neben Quinolin, das bereits unter Beobachtung von OEKO-TEX® stand, der Weichmacher und Viskositätsregulator TCEP (Tris(2-chlorethyl) phosphat), das Treibmittel ADCA (Azodicarboxamid) sowie die Siloxane D4, D5 und D6. In Anhang 6 neu aufgenommen wurden die Arylamine 4-Chloro-o-toluidinium chloride, CAS No. 3165-93-3, 2-Naphthylammoniumacetate, CAS No. 553-00-4, 2,4-Diaminoanisole sulphate, CAS No. 39156-41-7, 2,4,5-Trimethylaniline hydrochloride, CAS No. 21436-97-5 sowie der Flammhemmer Dinatriumoctaborat, CAS No. 12008-41-2.

Neuerungen in den Grenzwertkatalogen
Im Anhang 4 des ECO PASSPORT by OEKO-TEX® wurden zudem Grenzwerte verschiedener Parameter verschärft. Dies betrifft vor allem das Ausgangsprodukt für die Herstellung von Farbstoffen Anilin, die Lösungsmittel N-Methyl-2-pyrrolidon (NMP), N,N-Dimethylacetamid (DMAC), N,N-Dimethylformamid (DMF), die Flammhemmer tra-, Penta-, Hexa- und Heptabromdiphenylether, diverse Flammschutzmittel sowie Per- und Polyfluorierte Verbindungen (PFCs). Auch für die Substanzen OPP, CMK, TCMTB für Lederchemikalien gab es Änderungen im Grenzwertkatalog.

Weitere wichtige Änderungen im OEKO-TEX® Produktportfolio:

OEKO-TEX® deckt die neue „REACH Anhang XVII CMR Gesetzgebung“ bereits ab
Durch die Umsetzung von Grenzwertanforderungen von Benzol, Amin-Salzen sowie Quinolin im STANDARD 100 by OEKO-TEX® und LEATHER STANDARD by OEKO-TEX® decken diese bereits jetzt die Anforderungen der neuen „REACH Anhang XVII CMR Gesetzgebung“ (Commission Regulation (EU) 2018/1513) ab.

Glyphosat steht unter Beobachtung
Ab 2019 stehen zwei neue Produktgruppen im STANDARD 100 by OEKO-TEX® und LEATHER STANDARD by OEKO-TEX® unter Beobachtung: Glyphosat und seine Salze sowie die krebserregenden N-Nitrosamine und N-Nitrosierbare Substanzen.

Ein kostenfreies Webinar mit detaillierten Informationen zu den Neuregelungen 2019 für sämtliche OEKO-TEX® Produkte ist unter www.oeko-tex.com/webinare abrufbar.

Originalmeldung direkt auf PresseBox lesen
Mehr von Firma PresseBox

SLM Solutions and Identify3D Cooperate to Develop End-to-End Integrity for Additive Manufacturing in the Digital Supply Chain

After announcing their first collaboration in 2018, Identify3D and SLM Solutions have expanded their cooperation to productize their current joint developments to secure intellectual property in the additive manufacturing process chain. As SLM Solutions looks to the future of metal AM and many of its customers focus on production with selective laser melting machines, the integration of Identify3D will provide a solution for data protection and licensing from design to manufacturing.

Identify3D software includes modules to protect, manage, enforce and trace data between design and creation on SLM Solutions’ machines. To defend from counterfeit procedures and the loss of intellectual property, data is secured in encrypted files offering the owner traceability of their designs as well as the transparency to know who is utilizing the file. Qualified processes are locked to limit operator error and ensure compliance, repeatability and quality control.

“Identify3D software integrates into users’ current workflows but offers a new level of process security,” stated Stephan Thomas, Co-Founder and Chief Strategy Officer at Identify3D. “Manufacturers can implement different strategies to limit the number of times a part can be printed, set an expiration date on the design and automatically delete files from machines after a build. Validity checks allow an audit of their design throughout the selective laser melting process.”

“SLM Solutions recognizes the trend as additive transforms manufacturing into a digital workflow,” said Dr. Gereon W. Heinemann, CTO of SLM Solutions Group AG. “By working together with Identify3D, we aim to offer users not only robust manufacturing systems, but a strategy to integrate both security and traceability which are essential elements to production manufacturing processes.”
 
About Identify3D
Identify3D Inc. de-risks digital manufacturing with a suite of solutions that protects the confidentiality and integrity of data throughout the digital manufacturing thread. Identify3D provides intellectual property protection, manufacturing repeatability and traceability — from initial design through to finished product. Identify3D delivers greater control over the digital manufacturing process, and ensures the integrity and authenticity of digital information across complex supply chains. The company is privately held and based in San Francisco. For more information, visit www.identify3d.com

Originalmeldung direkt auf PresseBox lesen
Mehr von Firma PresseBox